Krakow, Poland – April 11, 2022 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced presentations from its most advanced oncology program RVU120 and MTA-cooperative PRMT5 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 in New Orleans, U.S.
Poster presentation details:
- Title: RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo
Session Title: Novel Targets and Pathways
Abstract Number: 2647
Date and Time: Tuesday, Apr 12, 2022, 9:00 AM – 12:30 PM
Location: Poster Section 24
- Title: Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers
Session Title: Drug Targets
Abstract Number: 1117
Date and Time: Monday, Apr 11, 2022, 1:30 PM – 5:00 PM
Location: Poster Section 23
- Title: Trials in Progress – RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors
Session Title: Phase II Trials in Progress
Abstract Number: 8023
Date and Time: Monday Apr 11, 2022 9:00 PM – 12:30 PM
Location: Poster Section 34
About RVU120 (SEL120)
RVU120 (also known as SEL120) is a clinical stage, highly specific and orally bioavailable dual inhibitor of CDK8/CDK19 kinases, which has demonstrated efficacy in a number of solid tumor in vitro and in vivo models as well as in hematologic malignancies.
At present, Ryvu is conducting two clinical studies with RVU120: (i) Phase Ib in patients with AML/HR-MDS (NCT04021368) and (ii) Phase I/II in relapsed/refractory metastatic or advanced solid tumors (NCT05052255). Additionally, multiple translational research activities are underway.
On March 25, 2020, the U.S. Food and Drug Administration (FDA) granted an orphan drug designation (ODD) to RVU120, for the treatment of patients with AML.
RVU120 has been internally discovered by Ryvu and has received support from the Leukemia & Lymphoma Society Therapy Acceleration Program® (TAP), a strategic initiative to partner directly with innovative biotechnology companies and leading research institutions to accelerate the development of promising new therapies for blood cancers.
Deletion of the metabolic gene MTAP occurs in 10 to 15% of all human tumors. Targeting PRMT5 in MTAP-deleted tumors in a synthetic lethal approach represents a promising antitumor strategy across many tumor types. Ryvu has identified a series of MTA-cooperative PRMT5 inhibitors which have good drug-like physicochemical properties and block methyltransferase activity of PRMT5 with nanomolar IC50 values. Ryvu’s compounds selectively inhibit growth of MTAP deleted cancer cells in prolonged 3D culture, which strongly correlates with inhibition of PRMT5-dependent protein symmetric demethylation in those cells.